Low C-peptide/glucose score during pregnancy together with prepregnancy obesity and severity of GDM (number of abnormal values in the 100-g diagnostic OGTT) are independent predictors of subsequent diabetes. Our data suggest that regardless of obesity and severity of GDM, a beta-cell defect increases the risk of postpartum diabetes. The association of postpartum glucose tolerance with triglyceride levels, blood pressure, obesity, and regional distribution of body fat suggests that postpartum glucose intolerance anticipates a high-risk cardiovascular profile that comprises other risk factors besides diabetes.
OBJECTIVE -The purpose of this study was to investigate the association of cardiovascular risk factors to impaired glucose tolerance (IGT) and to impaired fasting glucose (IFG) in women with prior gestational diabetes mellitus (GDM).RESEARCH DESIGN AND METHODS -We studied 838 women with prior GDM. Postpartum glucose tolerance status was classified as normal, IFG, IGT, IFG plus IGT, and diabetes according to the World Health Organization criteria. Postpartum BMI, waist circumference, blood pressure, triglyceride, cholesterol, and HDL cholesterol were assessed.RESULTS -BMI and blood pressure were significantly higher in women with IFG than in women with normal glucose status. BMI and waist circumference were significantly higher in women with IFG plus IGT than in women with normal glucose status. No differences were observed between women with IGT and normal glucose status. The prevalence of hypertension and obesity was significantly increased in IFG compared with normal glucose status. The prevalence of obesity and abnormal lipids was significantly increased in IFG plus IGT compared with normal glucose status. IGT showed no increased prevalence of cardiovascular risk factors.CONCLUSIONS -Traditional cardiovascular risk factors have a stronger association with isolated IFG than with isolated IGT in women with prior GDM.
Diabetes Care 26:2318 -2322, 2003W omen with gestational diabetes mellitus (GDM) are at an increased risk for the development of diabetes (usually type 2) after pregnancy (1). Likewise, women with prior GDM, when compared with women with no history of GDM, are found to have higher BMI (2), higher blood pressure (3,4), and an altered lipid profile with increased LDL cholesterol and triglyceride levels and decreased HDL cholesterol levels (2-4). Furthermore, changes in endothelial function (5) and increased levels of adhesion molecules (6), together with a higher prevalence of microalbuminuria (7), abnormal electrocardiograms, and cardiovascular events (3) are observed in women with prior GDM. This spectrum of abnormalities is associated with insulin resistance even in situations of normal glucose tolerance (8,9).On the other hand, the establishment of two intermediate categories between normal glucose homeostasis and diabetes (impaired glucose tolerance [IGT] and impaired fasting glucose [IFG]) (10) has raised concern in which of these disturbances has a major role in predicting the development of type 2 diabetes or cardiovascular disease.The aim of this study was to investigate the association of cardiovascular risk factors to IGT and IFG in the postpartum evaluation of women with GDM.
RESEARCH DESIGN AND METHODS -This research was conducted in the Diabetes and PregnancyUnit at the University Hospital La Paz in Madrid between 1992 and 2000. We studied 838 Caucasian women (mean age 32.4 Ϯ 4.6 years; mean parity 1.8 Ϯ 0.9) with singleton gestations complicated by GDM and who attended the initial postpartum assessment (3-6 months after delivery) when lactation was concluded. The total number of women...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.